StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Sunday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.8 %

Shares of NYSE:BTX opened at $1.11 on Friday. The company has a 50-day moving average price of $1.46 and a 200 day moving average price of $1.79. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10. The company has a market cap of $65.30 million, a P/E ratio of -0.49 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.